Background Macrophage migration inhibitory factor （MIF） is an upstream regulator in immune and inflammatory responses.However,its role in viral myocarditis remains unknown.In this study,we investigated the role of t...Background Macrophage migration inhibitory factor （MIF） is an upstream regulator in immune and inflammatory responses.However,its role in viral myocarditis remains unknown.In this study,we investigated the role of the MIF in coxsackievirus B3 （CVB3）-induced myocarditis.Methods Mice were randomized into two groups receiving either Eagle＇s minimal essential medium （EMEM,control group） or virus solution （infected group）.Subsets of mice in the infected group were sacrificed on days 3,7,14 and 28 after inoculation.Expression of MIF was detected using an enzyme-linked immunosorbent assay （ELISA）,reverse transcription polymerase chain reaction and immunohistochemistry.A neutralizing antibody （Ab） to MIF was injected intraperitoneally from day 0 to 7 after inoculation.Disease severity was estimated by histopathology of the heart and by the heart weight to body weight ratio,and the interleukin-1β （IL-1β） and tumor necrosis factor α （TNF-α） in the myocardium were measured by ELISA on day 14.Results The serum MIF concentration and expression levels of myocardial MIF mRNA and protein were significantly elevated in mice on days 7 and 14 post-infection.The survival rate was markedly higher and disease severity was obviously less in mice treated with anti-MIF Ab.Furthermore,MIF blockade significantly decreased the IL-1β and TNF-α in the myocarditic heart.Conclusion These results demonstrate that MIF is an important naturally occurring inflammatory cytokine in CVB3-induced myocarditis,and anti-MIF Ab may lessen the inflammatory response.展开更多
Objective: To evaluate the efficacy and safety of Chinese medicine(CM) plus Western medicine(WM) in the treatment of pediatric patients with severe hand, foot and mouth disease(HFMD) by conducting a prospective, contr...Objective: To evaluate the efficacy and safety of Chinese medicine(CM) plus Western medicine(WM) in the treatment of pediatric patients with severe hand, foot and mouth disease(HFMD) by conducting a prospective, controlled, and randomized trial. Methods: A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone(224 cases, WM therapy group) or CM [Reduning Injection(热毒宁注射液) or Xiyanping Injection(喜炎平注射液)] plus WM therapy(227 cases, CM plus WM therapy group) for 7–10 days, according to a web-based randomization system. The primary outcome was fever clearance time, which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h, as well as the rate for cough, runny nose, lethargy and weakness, agitation or irritability, and vomiting clearance within 120 h. The drug-related adverse events were also recorded. Results: The temperature decreased half-life time was 40.4 h in the WM therapy group, significantly longer than 27.2 h in the CM plus WM therapy group(P<0.01). Moreover, the rate for rash/herpes disappearance within 120 h was 43.6%(99/227) in the CM plus WM therapy group, significantly higher than 29.5%(66/224) in the WM therapy group(P<0.01). In addition, the rate for cough, lethargy and weakness, agitation or irritability disappearance within 120 h was 32.6%(74/227) in the CM plus WM therapy group, significantly higher than 19.2%(43/224) in the WM therapy group(P<0.01). No drug-related adverse events were observed during the course of the study. Conclusions: The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD.展开更多
基金This study was supported by the grants from the National Natural Science Foundation of China （No. 30271665）, and the Plan Project of Hunan Provincial Science ＆ Technology Department of China （No. 2009JT4010）.
文摘Background Macrophage migration inhibitory factor （MIF） is an upstream regulator in immune and inflammatory responses.However,its role in viral myocarditis remains unknown.In this study,we investigated the role of the MIF in coxsackievirus B3 （CVB3）-induced myocarditis.Methods Mice were randomized into two groups receiving either Eagle＇s minimal essential medium （EMEM,control group） or virus solution （infected group）.Subsets of mice in the infected group were sacrificed on days 3,7,14 and 28 after inoculation.Expression of MIF was detected using an enzyme-linked immunosorbent assay （ELISA）,reverse transcription polymerase chain reaction and immunohistochemistry.A neutralizing antibody （Ab） to MIF was injected intraperitoneally from day 0 to 7 after inoculation.Disease severity was estimated by histopathology of the heart and by the heart weight to body weight ratio,and the interleukin-1β （IL-1β） and tumor necrosis factor α （TNF-α） in the myocardium were measured by ELISA on day 14.Results The serum MIF concentration and expression levels of myocardial MIF mRNA and protein were significantly elevated in mice on days 7 and 14 post-infection.The survival rate was markedly higher and disease severity was obviously less in mice treated with anti-MIF Ab.Furthermore,MIF blockade significantly decreased the IL-1β and TNF-α in the myocarditic heart.Conclusion These results demonstrate that MIF is an important naturally occurring inflammatory cytokine in CVB3-induced myocarditis,and anti-MIF Ab may lessen the inflammatory response.
基金Supported by the Research Project of State Administration of Traditional Chinese Medicine,China(No.200907001-3)
文摘Objective: To evaluate the efficacy and safety of Chinese medicine(CM) plus Western medicine(WM) in the treatment of pediatric patients with severe hand, foot and mouth disease(HFMD) by conducting a prospective, controlled, and randomized trial. Methods: A total of 451 pediatric patients with severe HFMD were randomly assigned to receive WM therapy alone(224 cases, WM therapy group) or CM [Reduning Injection(热毒宁注射液) or Xiyanping Injection(喜炎平注射液)] plus WM therapy(227 cases, CM plus WM therapy group) for 7–10 days, according to a web-based randomization system. The primary outcome was fever clearance time, which was presented as temperature decreased half-life time. The secondary outcomes included the rate of rash/herpes disappearance within 120 h, as well as the rate for cough, runny nose, lethargy and weakness, agitation or irritability, and vomiting clearance within 120 h. The drug-related adverse events were also recorded. Results: The temperature decreased half-life time was 40.4 h in the WM therapy group, significantly longer than 27.2 h in the CM plus WM therapy group(P<0.01). Moreover, the rate for rash/herpes disappearance within 120 h was 43.6%(99/227) in the CM plus WM therapy group, significantly higher than 29.5%(66/224) in the WM therapy group(P<0.01). In addition, the rate for cough, lethargy and weakness, agitation or irritability disappearance within 120 h was 32.6%(74/227) in the CM plus WM therapy group, significantly higher than 19.2%(43/224) in the WM therapy group(P<0.01). No drug-related adverse events were observed during the course of the study. Conclusions: The combined CM and WM therapy achieved a better therapeutic efficacy in treating severe HFMD than the WM therapy alone. Reduning or Xiyanping Injections may become an important complementary therapy to WM for relieving the symptoms of severe HFMD.
